Meeting
2016 ASCO Annual Meeting
Decreased copy number aberrations in genomes of HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary durable complete responses (dCR) to trastuzumab (T).
Authors
Alanna Maguire
National Institute for Cellular Biotechnology, Dublin, Ireland
Alanna Maguire , Giuseppe Gullo , Cecily Quinn , Smriti Malasi , Elizabeth Lenkiewicz , Michael T. Barrett , Norma O'Donovan , Naomi Walsh , John Crown
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 610)
DOI
10.1200/JCO.2016.34.15_suppl.610
Abstract #
610
Poster Bd #
98
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.
First Author: Charlotte Andrieu
First Author: Nicholas Patrick McAndrew
Poster
2023 ASCO Annual Meeting
Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).
First Author: Hyo S. Han
Poster
2023 ASCO Annual Meeting
Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC).
First Author: Qianyu Yuan